Revance Therapeutics Management
Management criteria checks 2/4
Revance Therapeutics' CEO is Mark Foley, appointed in Oct 2019, has a tenure of 4.42 years. total yearly compensation is $10.07M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth $5.46M. The average tenure of the management team and the board of directors is 4.4 years and 4.7 years respectively.
Key information
Mark Foley
Chief executive officer
US$10.1m
Total compensation
CEO salary percentage | 7.2% |
CEO tenure | 4.4yrs |
CEO ownership | 1.1% |
Management average tenure | 4.4yrs |
Board average tenure | 4.7yrs |
Recent management updates
Recent updates
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You
Mar 04Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
Feb 29Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%
Dec 28Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be
Nov 10Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt
Aug 10Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors
Jun 14Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Apr 17Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Jan 02Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
Oct 20Revance climbs 14% as FDA approves facial injectable for frown lines
Sep 08Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems
Aug 24Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Aug 04Revance: Potential Comeback On FDA Resubmission For DAXI
Jul 15Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Apr 17CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$10m | US$720k | -US$324m |
Sep 30 2023 | n/a | n/a | -US$414m |
Jun 30 2023 | n/a | n/a | -US$358m |
Mar 31 2023 | n/a | n/a | -US$352m |
Dec 31 2022 | US$7m | US$673k | -US$356m |
Sep 30 2022 | n/a | n/a | -US$274m |
Jun 30 2022 | n/a | n/a | -US$263m |
Mar 31 2022 | n/a | n/a | -US$274m |
Dec 31 2021 | US$7m | US$660k | -US$281m |
Sep 30 2021 | n/a | n/a | -US$297m |
Jun 30 2021 | n/a | n/a | -US$303m |
Mar 31 2021 | n/a | n/a | -US$292m |
Dec 31 2020 | US$9m | US$650k | -US$282m |
Sep 30 2020 | n/a | n/a | -US$249m |
Jun 30 2020 | n/a | n/a | -US$209m |
Mar 31 2020 | n/a | n/a | -US$186m |
Dec 31 2019 | US$18m | US$190k | -US$159m |
Sep 30 2019 | n/a | n/a | -US$155m |
Jun 30 2019 | n/a | n/a | -US$146m |
Mar 31 2019 | n/a | n/a | -US$143m |
Dec 31 2018 | US$243k | n/a | -US$143m |
Sep 30 2018 | n/a | n/a | -US$138m |
Jun 30 2018 | n/a | n/a | -US$136m |
Mar 31 2018 | n/a | n/a | -US$128m |
Dec 31 2017 | US$338k | n/a | -US$121m |
Compensation vs Market: Mark's total compensation ($USD10.07M) is above average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark Foley (58 yo)
4.4yrs
Tenure
US$10,068,915
Compensation
Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 4.4yrs | US$10.07m | 1.06% $ 5.5m | |
President | 2.3yrs | US$4.58m | 0.16% $ 827.7k | |
CFO & Principal Accounting Officer | 5.3yrs | US$3.97m | 0.092% $ 474.3k | |
Chief Legal Officer & General Counsel | 4.1yrs | US$3.53m | 0.046% $ 236.2k | |
Head of Investor Relations & ESG | no data | no data | no data | |
Senior Director of Investor Relations & Corporate Communications | 7.3yrs | no data | no data | |
Vice President of Marketing | 4.9yrs | no data | no data | |
Chief People Officer | less than a year | no data | no data | |
Head of Medical Affairs & Aesthetics | 5.8yrs | no data | no data | |
Chief Medical Officer of Global Therapeutics Franchise Lead | 1.2yrs | no data | 0.0058% $ 29.8k | |
Chief Commercial Officer | no data | no data | 0.0089% $ 46.0k |
4.4yrs
Average Tenure
47.5yo
Average Age
Experienced Management: RVNC's management team is considered experienced (4.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 6.5yrs | US$10.07m | 1.06% $ 5.5m | |
Independent Chairman | 10yrs | US$346.03k | 0.035% $ 180.3k | |
Independent Director | 4.8yrs | US$317.53k | 0.027% $ 141.3k | |
Independent Director | 7.7yrs | US$305.03k | 0.029% $ 148.7k | |
Independent Director | less than a year | no data | 0.0056% $ 28.6k | |
Independent Director | 3yrs | US$295.03k | 0.016% $ 82.4k | |
Independent Director | 3yrs | US$284.51k | 0.016% $ 81.8k | |
Independent Director | 4.7yrs | US$315.03k | 0.027% $ 141.3k |
4.7yrs
Average Tenure
64yo
Average Age
Experienced Board: RVNC's board of directors are considered experienced (4.7 years average tenure).